Is Eli Lilly and Company Stock (LLY) Overbought or Oversold?
RSI analysis computed from LLY's daily closing prices · Data through October 15, 2026
As of October 15, 2026, LLY’s 14-day RSI is 67.9, inside the neutral 30–70 band — neither overbought nor oversold by the conventional thresholds.
RSI-14 Scale
LLY reads 67.9 on the 0–100 scale.
The Supporting Picture
vs 50-Day MA
+6.2%
MA: $1179.27
vs 200-Day MA
+18.0%
MA: $1061.43
From 52-Wk High
-2.2%
High: $1280.44
Volume vs 20-Day Avg
-63%
Avg: 1.6M shares
The 50-day average is currently above the 200-day average, which technicians read as a longer-term uptrend backdrop for the RSI reading above.
What's Behind the Reading
October 15, 2026Eli Lilly's current RSI of 67.89, while in the neutral zone, reflects robust upward momentum, with the stock trading 6.2% above its 50-day moving average and just 2.22% shy of its 52-week high. The stock experienced a notable 3.7% increase on October 15, 2026, driven by positive pipeline developments and strategic pre-earnings positioning. This follows a 3.3% rise on October 14, 2026, fueled by favorable analyst sentiment regarding a new clinical trial collaboration and optimistic projections for global cancer drug spending. The company's highly successful weight-loss and diabetes medications, such as Zepbound and Mounjaro, have been significant revenue drivers, contributing to its market capitalization surpassing $1 trillion in late 2025. Recent product news includes new data for Taltz and Zepbound in psoriasis and obesity, and an expanded FDA indication for Jaypirca in CLL/SLL.
Recent Overbought / Oversold Episodes
How LLY behaved the last few times RSI left the neutral band — including its return over the 5 trading days after each episode ended.
| Episode | Period | Next 5 Days |
|---|---|---|
| overbought | June 29, 2026 – July 7, 2026 | -6.6% |
| oversold | March 27, 2026 | +35.7% |
| overbought | November 3, 2025 – November 28, 2025 | -6.1% |
| overbought | October 3, 2025 – October 9, 2025 | -4.2% |
Past behavior does not predict future results — small sample sizes especially.
Frequently Asked Questions
Is Eli Lilly and Company (LLY) overbought right now?
What is RSI (Relative Strength Index)?
Is an overbought stock a sell signal?
How often is this page updated?
Where does this data come from?
Methodology
The verdict on this page is mechanical: we compute the 14-day Relative Strength Index with Wilder’s smoothing from LLY’s daily closing prices, and apply the conventional thresholds — above 70 is overbought, below 30 is oversold. Moving averages, the 52-week range, and volume comparisons come from the same price history.
Indicators are recomputed after every market close. The AI commentary adds context from current news via grounded search, but never changes the computed verdict. Note: closes are as-traded; a stock split would distort readings for a few weeks until the window rolls past it.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on LLY
Eli Lilly and Company Overview
Price, chart, analysis & financials
LLY: Why Is It Moving?
Updated daily
LLY: Price Prediction
Updated daily
LLY: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers